Esperion Therapeutics(ESPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ESPR Esperion Therapeutics

Not Yet Opened 01-12 16:00:00 EST

3.55

-0.33

-8.51%

盘后3.58

+0.03+0.85%

19:59 EST

High3.91	Low3.54	Vol9.22M
Open3.91	D1 Closing3.88	Amplitude9.41%
Mkt Cap848.68M	Tradable Cap841.35M	Total Shares239.06M
T/O33.52M	T/O Rate3.89%	Tradable Shares237.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ESPR","market":"US","secType":"STK","nameCN":"Esperion Therapeutics","latestPrice":3.55,"timestamp":1768251600000,"preClose":3.88,"halted":0,"volume":9221412,"hourTrading":{"tag":"盘后","latestPrice":3.5802,"preClose":3.55,"latestTime":"19:59 EST","volume":87874,"amount":313873.7151,"timestamp":1768265992558},"delay":0,"floatShares":237000000,"shares":239063437,"eps":-0.535792,"marketStatus":"Not Yet Opened","change":-0.33,"latestTime":"01-12 16:00:00 EST","open":3.905,"high":3.905,"low":3.54,"amount":33518941.831600796,"amplitude":0.094072,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.535792,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768294800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1372219200000,"exchange":"NASDAQ","adjPreClose":3.88,"preHourTrading":{"tag":"盘前","latestPrice":3.87,"preClose":3.88,"latestTime":"09:29 EST","volume":14428,"amount":56549.5259404,"timestamp":1768228199999},"postHourTrading":{"tag":"盘后","latestPrice":3.5802,"preClose":3.55,"latestTime":"19:59 EST","volume":87874,"amount":313873.7151,"timestamp":1768265992558},"volumeRatio":1.743895,"impliedVol":0.9849,"impliedVolPercentile":0.6813},"requestUrl":"/m/hq/s/ESPR","defaultTab":"news","newsList":[{"id":"2602566173","title":"Esperion reports preliminary FY25 revenue $400M-$408M, consensus $393.11M","url":"https://stock-news.laohu8.com/highlight/detail?id=2602566173","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602566173?lang=en_us&edition=fundamental","pubTime":"2026-01-12 08:25","pubTimestamp":1768177516,"startTime":"0","endTime":"0","summary":"“2025 marked the most successful year in Esperion’s (ESPR) history, driven by exceptional execution across our U.S. commercial strategy, expanded g...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/esperion-reports-preliminary-fy25-revenue-400m-408m-consensus-393-11m-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/esperion-reports-preliminary-fy25-revenue-400m-408m-consensus-393-11m-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ESPR"],"gpt_icon":0},{"id":"2602563452","title":"BRIEF-Esperion Reports $156 To $160 Million In Preliminary Full-Year 2025 U.S. Net Product Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2602563452","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602563452?lang=en_us&edition=fundamental","pubTime":"2026-01-12 07:04","pubTimestamp":1768172662,"startTime":"0","endTime":"0","summary":"BRIEF-Esperion Reports $156 To $160 Million In Preliminary Full-Year 2025 U.S. Net Product SalesJan 11 (Reuters) - Esperion Therapeutics Inc ESPR.O:ESPERION PROVIDES BUSINESS UPDATE AT 44TH ANNUAL J.P","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUA7LMSHG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"gpt_icon":0},{"id":"2602174563","title":"Esperion Therapeutics Projects 2025 Revenue Up to $408 Million and Operating Expenses Up to $245 Million for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602174563","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602174563?lang=en_us&edition=fundamental","pubTime":"2026-01-12 07:00","pubTimestamp":1768172415,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics Inc. released its preliminary financial outlook for full-year 2025, projecting U.S. net product sales between $156 million and $160 million, representing a 35% to 38% increase compared to 2024. Total preliminary revenue is expected to reach $400 million to $408 million, up 20% to 23% year-over-year, and reflecting approximately 55% to 59% growth when excluding one-time milestone payments. The company reported cash and cash equivalents of approximately $168 million at year-end 2025. Operating expenses for full-year 2026 are anticipated to be between $210 million and $245 million. Esperion highlighted significant growth in its cardiovascular franchise and retail prescription equivalents, which increased 34% year-over-year and 11.3% quarter-over-quarter in Q4.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nNDL3yCSNy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B3QW5Z07.USD","ESPR","LU2095319765.USD","SG9999014021.USD","SG9999014039.USD","IE00BGHQF748.EUR","LU0314104364.USD","SG9999014005.SGD","BK4585","IE00B64PRP62.GBP","NDAQ","SG9999014013.SGD","BK4588","LU2210149790.SGD","BK4007","LU2210150020.SGD","BK4112"],"gpt_icon":0},{"id":"2602451563","title":"Esperion Therapeutics Inc - Reports $156 to $160 Mln in Preliminary* Full-Year 2025 U.S. Net Product Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2602451563","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602451563?lang=en_us&edition=fundamental","pubTime":"2026-01-12 07:00","pubTimestamp":1768172401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUA7LMSHG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2602178563","title":"Esperion Provides Business Update at 44TH Annual J.p. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602178563","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602178563?lang=en_us&edition=fundamental","pubTime":"2026-01-12 07:00","pubTimestamp":1768172401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUA7LMSHG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2602563457","title":"Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602563457","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602563457?lang=en_us&edition=fundamental","pubTime":"2026-01-12 07:00","pubTimestamp":1768172400,"startTime":"0","endTime":"0","summary":"– Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 – –Total Preliminary* Revenue of $400 to $408 million, a 20% to","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/11/3216503/0/en/Esperion-Provides-Business-Update-at-44th-Annual-J-P-Morgan-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1791710582.SGD","LU0320765646.SGD","LU1989772840.SGD","BK4137","LU2111349929.HKD","LU0158827781.USD","LU0128526141.USD","LU1244550577.SGD","LU2357305700.SGD","LU0882574139.USD","LU1074936037.SGD","HCSG","LU0106831901.USD","LU0234570918.USD","LU2133065610.SGD","LU1791710400.SGD","LU0098860793.USD","BK4588","LU1162221912.USD","LU1732800096.USD","BK4516","LU0106261372.USD","PSC","LU0029874061.USD","LU0267386448.USD","LU1668664300.SGD","BK4534","ESPR","LU2023251221.USD","IE00BKVL7J92.USD","LU2089284900.SGD","LABU","LU1732799900.SGD","CV","LU1720051017.SGD","BK4581","LU0795875086.SGD","IE00BZ1G4Q59.USD","XLV","XBI","LU2028103732.USD","LU2271345857.HKD","LU0971096721.USD","LU0006306889.USD","LU0528227936.USD","LU0225283273.USD","BK4127","LU1989772923.USD","LU0912757837.SGD","BK4082"],"gpt_icon":0},{"id":"2590632216","title":"BRIEF-Esperion Announces Inducement Grants Under Nasdaq Listing Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2590632216","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590632216?lang=en_us&edition=fundamental","pubTime":"2025-12-10 06:13","pubTimestamp":1765318386,"startTime":"0","endTime":"0","summary":"BRIEF-Esperion Announces Inducement Grants Under Nasdaq Listing Rule Dec 9 (Reuters) - Esperion Therapeutics Inc ESPR.O:ESPERION ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)Source text: ID:nGNXbsRbLzFurther company coverage: ESPR.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA6S64WZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"gpt_icon":0},{"id":"2590647324","title":"Esperion Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590647324","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590647324?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:30","pubTimestamp":1765315801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA6S64WZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ESPR"],"gpt_icon":0},{"id":"2590132288","title":"Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590132288","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590132288?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:30","pubTimestamp":1765315800,"startTime":"0","endTime":"0","summary":"ANN ARBOR, Mich., Dec.  09, 2025  (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on December 4, 2025, the Company granted three new employees (i) non-qualified stock options to purch","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202793/0/en/Esperion-Announces-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":[".IXIC","BK4007","TSYW.SI","MNQmain","SQQQ","PSQ","ESPR","QID","QLD","TQQQ","USJW.SI","NVIW.SI","USAW.SI","NQmain"],"gpt_icon":1},{"id":"2586036204","title":"Esperion Therapeutics Shares Rise After Piper Sandler Initiates Coverage","url":"https://stock-news.laohu8.com/highlight/detail?id=2586036204","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586036204?lang=en_us&edition=fundamental","pubTime":"2025-11-26 02:41","pubTimestamp":1764096093,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics  shares were up over 15% in recent Tuesday trading after Piper Sandler began coverage of the healthcare company's stock with an overweight rating and a $9 price target.The company's trading volume for the day stood at about 13.8 million shares against a daily average of roughly 7 million.Price: 3.67, Change: +0.50, Percent Change: +15.62","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2586724874","title":"BUZZ-U.S. STOCKS ON THE MOVE-Applied Materials, CDW,  Kohl's","url":"https://stock-news.laohu8.com/highlight/detail?id=2586724874","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586724874?lang=en_us&edition=fundamental","pubTime":"2025-11-25 23:45","pubTimestamp":1764085504,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Applied Materials, CDW, Kohl'sEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: htt","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nL6N3X10WK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","UPWK","LU0784383803.USD","BK4548","SG9999000418.SGD","FLY","APD","KEYS","LU1066051498.USD","FIBK","LU0323591593.USD","LIXT","FCX","LU1815336760.USD","SCCO","ESPR","ADI","SRPT","IE00BN0W2T93.GBP","TITN","SPOT","CDW","LU2290526834.HKD","DD","BBY","FLNC","PTCT","CDE","ABCB","ZM","ALUR","ZETA","ATAT","KSS","ANF","AMAT","HL","LU1116320737.USD","VST","SYM","BK4541"],"gpt_icon":1},{"id":"2586026479","title":"Esperion Therapeutics Initiated at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2586026479","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586026479?lang=en_us&edition=fundamental","pubTime":"2025-11-25 22:29","pubTimestamp":1764080940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ESPR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 25, 2025 09:29 ET (14:29 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR"],"gpt_icon":0},{"id":"2586442049","title":"Piper Sandler Initiates Coverage on Esperion Therapeutics With Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2586442049","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586442049?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:16","pubTimestamp":1764072993,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics (ESPR) has an average rating of overweight and mean price target of $6.47, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ESPR"],"gpt_icon":0},{"id":"2586427196","title":"BUZZ-Esperion gains after Piper Sandler initiates with 'overweight' rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2586427196","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586427196?lang=en_us&edition=fundamental","pubTime":"2025-11-25 19:50","pubTimestamp":1764071412,"startTime":"0","endTime":"0","summary":"BUZZ-Esperion gains after Piper Sandler initiates with 'overweight' rating** Shares of drug developer Esperion Therapeutics ESPR.O gain 1.4% to $3.22 premarket** Piper Sandler initiates with \"overweig","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nL4N3X10P2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PIPR","BK4127","ESPR"],"gpt_icon":0},{"id":"2586429701","title":"Esperion initiated with an Overweight at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2586429701","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586429701?lang=en_us&edition=fundamental","pubTime":"2025-11-25 18:10","pubTimestamp":1764065428,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst David Amsellem last night initiated coverage of Esperion (ESPR) with an Overweight rating and $9 price target The company’s b...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/esperion-initiated-with-an-overweight-at-piper-sandler-thefly-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/esperion-initiated-with-an-overweight-at-piper-sandler-thefly-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2586086442","title":"U.S. RESEARCH ROUNDUP-Air Products, Hanover Insurance, Kinsale Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2586086442","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586086442?lang=en_us&edition=fundamental","pubTime":"2025-11-25 15:29","pubTimestamp":1764055799,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Air Products, Hanover Insurance, Kinsale CapitalNov 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, inclu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nL4N3X10CW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRT","LU2092937221.SGD","LU2322448791.USD","CUZ","NWSA","LU1543694498.USD","THG","KEYS","BK4560","BK4179","OKTA","LU0238689110.USD","SNEX","MMC","EPRT","BK4173","INSP","LUMN","BK4548","SIGI","HIG","CENT","DEI","HL","BK4588","APD","BK4549","SMTC","BK4007","EXAS","LU0106261612.USD","BOW","LU2272731782.SGD","BJ","LU2413666699.HKD","A","COCO","ZM","EHTH","ESPR","TWFG","LU1169589451.USD","LU2041044095.USD","BK4223","BK4082","LU2272731865.HKD","KNSL","LMND","AXGN","IE00BMPRXR70.SGD"],"gpt_icon":0},{"id":"2586445056","title":"Esperion Therapeutics Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $9","url":"https://stock-news.laohu8.com/highlight/detail?id=2586445056","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586445056?lang=en_us&edition=fundamental","pubTime":"2025-11-25 12:43","pubTimestamp":1764045802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nFWN3X00NU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ESPR"],"gpt_icon":0},{"id":"2585128696","title":"BUZZ-U.S. STOCKS ON THE MOVE-IES Holding, Eli Lilly, Alphabet","url":"https://stock-news.laohu8.com/highlight/detail?id=2585128696","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585128696?lang=en_us&edition=fundamental","pubTime":"2025-11-22 02:44","pubTimestamp":1763750694,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-IES Holding, Eli Lilly, AlphabetEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: h","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nL6N3WX0O1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LOW","GAP","NVDS","LU0868494708.USD","NVD2.UK","ESPR","NFE","NVDY","WDAY","NVIW.SI","BBWI","SNVD.UK","CPRT","LU0957808578.USD","INTU","VFS","OGE","RIOT","NVDU","3NVD.UK","AHR","LU1880398471.USD","NVD","NVDS.UK","2NVD.UK","AZTA","NVRI","ANAB","IESC","DOCS","NVD3.UK","BJ","PHM","GOOGL","TMUS","NVDD","DHI"],"gpt_icon":1},{"id":"2585145382","title":"BRIEF-Esperion Partner Otsuka Launches Nexletol In Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2585145382","media":"Reuters","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585145382?lang=en_us&edition=fundamental","pubTime":"2025-11-21 21:20","pubTimestamp":1763731255,"startTime":"0","endTime":"0","summary":"BRIEF-Esperion Partner Otsuka Launches Nexletol In JapanNov 21 (Reuters) - Esperion Therapeutics Inc ESPR.O:ESPERION PARTNER OTSUKA LAUNCHES NEXLETOL IN JAPAN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nTUA1YXTQD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2585143690","title":"Esperion Receives $90 Million Payment as Otsuka Launches NEXLETOL in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2585143690","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585143690?lang=en_us&edition=fundamental","pubTime":"2025-11-21 21:00","pubTimestamp":1763730016,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Esperion Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 21, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDLCGt7y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4112","BK4588","LU2210150020.SGD","LU0314104364.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4007","NDAQ","LU2210149790.SGD","BK4585","ESPR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.esperion.com","stockEarnings":[{"period":"1week","weight":-0.0682},{"period":"1month","weight":-0.0779},{"period":"3month","weight":0.3148},{"period":"6month","weight":2.1696},{"period":"1year","weight":0.5171},{"period":"ytd","weight":-0.0405}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":-0.040076},{"month":2,"riseRate":0.5,"avgChangeRate":0.124334},{"month":3,"riseRate":0.5,"avgChangeRate":-0.027865},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.028114},{"month":5,"riseRate":0.666667,"avgChangeRate":-0.032489},{"month":6,"riseRate":0.75,"avgChangeRate":0.035061},{"month":7,"riseRate":0.461538,"avgChangeRate":-0.001019},{"month":8,"riseRate":0.461538,"avgChangeRate":0.026549},{"month":9,"riseRate":0.538462,"avgChangeRate":-0.000828},{"month":10,"riseRate":0.538462,"avgChangeRate":-0.017419},{"month":11,"riseRate":0.692308,"avgChangeRate":0.148542},{"month":12,"riseRate":0.461538,"avgChangeRate":0.067177}],"exchange":"NASDAQ","name":"Esperion Therapeutics","nameEN":"Esperion Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Esperion Therapeutics(ESPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Esperion Therapeutics(ESPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Esperion Therapeutics,ESPR,Esperion Therapeutics股票,Esperion Therapeutics股票老虎,Esperion Therapeutics股票老虎国际,Esperion Therapeutics行情,Esperion Therapeutics股票行情,Esperion Therapeutics股价,Esperion Therapeutics股市,Esperion Therapeutics股票价格,Esperion Therapeutics股票交易,Esperion Therapeutics股票购买,Esperion Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Esperion Therapeutics(ESPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Esperion Therapeutics(ESPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}